Lodinews.com

default avatar
Welcome to the site! Login or Signup below.
|
||
Logout|My Dashboard

When it comes to treating his CML, Kareem Abdul-Jabbar shoots and scores

Print
Font Size:
Default font size
Larger font size

Posted: Monday, December 17, 2012 10:00 pm | Updated: 1:40 am, Wed Dec 19, 2012.

(BPT) - The story of NBA's All-Time Leading Scorer Kareem Abdul-Jabbar’s diagnosis with chronic myeloid leukemia (CML) is one example of how a devastating diagnosis can be turned into advocacy and inspiration. 

In 2008, Mr. Abdul-Jabbar knew something was wrong. He was experiencing hot flashes and at night would wake up soaked in sweat. He knew it was time to make an appointment with his doctor. After a series of tests, he quickly learned that he had Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). Mr. Abdul-Jabbar explains:

“When I first heard that I had cancer, I was in shock and it felt like I’d been given a death sentence. But my doctor explained that by working closely together to develop the right treatment plan, including establishing clear treatment goals and taking medication as prescribed, my disease can be treated.”

CML is a cancer of the blood and bone marrow in which the body produces cancerous white blood cells. Chronic means a relatively slower-growing cancer that may take years to progress. Myeloid refers to the type of white blood cell being overproduced. In 2012 alone, there will be more than 5,430 newly diagnosed cases of this form of leukemia in the United States, according to the American Cancer Society.

Over the past 12 years, there have been significant advances in understanding how CML works, which has led to the development of treatments designed to act against the underlying cause of this disease, a genetic abnormality called Bcr-Abl. These treatments, known as Bcr-Abl inhibitors, are thought to block the ability of the abnormal Bcr-Abl gene to send signals that drive production of the leukemic blood cells.

And while there have been many advances in the treatment of CML, it’s important that patients be actively involved in the management of their disease by working closely with their doctor to ensure they are reaching their personal treatment goals. For those patients living with CML, a key treatment goal is to achieve and maintain a major molecular response, or MMR, which means that the amount of BCR-ABL in your blood or bone marrow is very low, or even nearly undetectable.

“For patients living with CML, it is very important to continue to monitor your disease. For example, my doctor and I recently determined I was not reaching my treatment goals -- to reach and sustain a molecular response and address the side effects I was experiencing -- with my current plan. We re-evaluated my treatment plan and after considering my options, decided to switch my medication. Since switching, I’ve been able to achieve and maintain a MMR with less fatigue and hand cramping.”

The most sensitive test that is currently available to measure MMR is a simple blood test called an International Scale-PCR test (IS-PCR stands for International Scale Polymerase Chain Reaction). Getting regular IS-PCR tests is an important part of your treatment plan, as it will help you and your doctor determine if you are achieving and maintaining a MMR.

Mr. Abdul-Jabbar notes, “For me, it’s important to play an active role in life and a part of my life is treating my CML. I now know that I have reached a molecular response with my CML treatment, and I’m fortunate that I’m still able to do many of the things I love to do.”

Learn more about CML visit www.cmlearth.com.

As a CML patient advocate, Kareem Abdul-Jabbar’s goal is to inspire and educate fellow patients living with this disease. In addition to his work on CML education, he is also an author and documentary filmmaker and a retired professional basketball player. Kareem was recently honored by the Los Angeles Lakers with a statue on the grounds of the Staples Center, the team’s home arena, to commemorate his accomplishments.

Rules of Conduct

  • 1 Use your real name. You must register with your full first and last name before you can comment. (And don't pretend you're someone else.)
  • 2 Keep it clean. Please avoid obscene, vulgar, lewd, racist or sexually oriented language.
  • 3 Don't threaten. Threats of harming another person will not be tolerated.
  • 4 Be truthful. Don't lie about anyone or anything. Don't post unsubstantiated allegations, rumors or gossip that could harm the reputation of a person, company or organization.
  • 5 Be nice. No racism, sexism or any sort of -ism that is degrading to another person.
  • 6 Stay on topic. Make sure your comments are about the story. Don't insult each other.
  • 7 Tell us if the discussion is getting out of hand. Use the 'Report' link on each comment to let us know of abusive posts.
  • 8 Share what you know, and ask about what you don't.

Welcome to the discussion.

    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days. You will see 10 articles for free before being asked to register, and then you can view 10 additional articles by registering or logging in. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days, and you currently have (%remaining%) free articles remaining ((%remaining_reg%) before being asked to register and (%remaining_sub%) before being asked to subscribe). Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days, and you currently have (%remaining%) free articles remaining ((%remaining_reg%) before being asked to register and (%remaining_sub%) before being asked to subscribe). Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days, and you currently have (%remaining%) total free articles remaining ((%remaining_reg%) before being asked to register and (%remaining_sub%) before being asked to subscribe). Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You have viewed (%viewed%) of your 20 free pages in 30 days. Please login or register at this time and enjoy the next (%remaining%) articles free of charge. After your 20 free articles, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. Because you have already viewed this article, you may view it again as many times as you would like without subtracting from your remaining free article views.
    (%remaining%) Remaining Thank you for registering on Lodinews.com. You're entitled to view 20 articles for free every 30 days, and you currently have (%remaining%) remaining. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You're entitled to view 20 articles for free every 30 days, and you currently have (%remaining%) remaining. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You're entitled to view 20 articles for free every 30 days, and you currently have (%remaining%) remaining. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You're entitled to view 20 articles for free every 30 days. This is your last free article this period. On your next article we'll ask you to purchase an affordable subscription.

    Poll

    Loading…

    Regional News

    Mailing List

    Subscribe to a mailing list to have daily news sent directly to your inbox.

    • News Updates

      Would you like to receive our daily news headlines? Sign up now!

    Manage Your Lists